10-Q: Ascend Wellness Q1 2026 Financial Results

Ascend Wellness Holdings reports Q1 2026 revenue of $116.9 million, reflecting a 9% year-over-year decline amid market competition.

Summary

• Reported net revenue of $116.9 million for Q1 2026, down 9% from $128.0 million in Q1 2025.
• Net loss for the quarter was $29.5 million, compared to a $19.3 million loss in the prior year period.
• Adjusted EBITDA was $26.3 million, representing an Adjusted EBITDA margin of 22.5%.
• Cash and cash equivalents stood at $60.9 million as of March 31, 2026.
• The company successfully resolved a major arbitration matter with Green Thumb Industries via a $17 million settlement payment.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging quarter characterized by revenue contraction and a significant net loss, though the resolution of the GTI arbitration provides a slight positive offset.

Positives

• Gross margin improved to 38.4% in Q1 2026 from 30.9% in Q1 2025.
• Adjusted Gross Margin increased to 46.1% compared to 40.8% in the prior year period.
• Successfully resolved the Green Thumb Industries arbitration, removing a significant legal uncertainty.
• Maintained liquidity sufficient to support operations for the next twelve months.

Negatives

• Revenue declined 9% year-over-year due to increased competition and pricing pressure in key markets.
• Net loss widened to $29.5 million from $19.3 million in the prior year.
• Operating cash flow was negative $19.4 million, impacted by a $17 million litigation settlement and high interest payments.
• Interest expense rose 81% to $20.3 million, largely due to finance lease obligations.

Risks

• Cannabis remains illegal under U.S. federal law, creating ongoing regulatory and tax uncertainty.
• Potential for the April 2026 DOJ rescheduling order to be challenged, enjoined, or vacated in court.
• Intense competition and price compression in core markets like Illinois, New Jersey, and Massachusetts.
• Exposure to high interest rates and debt service obligations.
• Ongoing litigation, including a complaint filed by the Ohio Attorney General regarding alleged anticompetitive collusion.

Future Outlook

The company is evaluating the impact of the April 2026 DOJ order on its medical cannabis operations, including potential tax relief under IRC Section 280E, but cannot currently estimate the financial impact. Management expects to fund 2026 capital expenditures of approximately $20 million primarily through operating cash flows.

Management Comments

• Management believes current cash and anticipated operating cash flows are adequate to support operations for the next twelve months.
• The company plans to vigorously contest the anticompetitive collusion claims filed by the Ohio Attorney General.

Industry Context

StockSavvy.ai notes that the cannabis sector is currently navigating a period of significant regulatory transition following the DOJ's move to reschedule medical cannabis to Schedule III. Ascend's results reflect broader industry trends of price compression and intense competition, while the company's focus on vertical integration remains a standard strategy for MSOs to manage margin pressure.

Comparison to Industry Standards

• The company's gross margin of 38.4% is generally competitive with other large-scale U.S. multi-state operators.
• The reliance on debt financing and high interest expenses is consistent with the capital-intensive nature of the U.S. cannabis industry due to limited access to traditional banking.

Corporate Governance

Legal Proceedings

• Settlement of arbitration with Green Thumb Industries for $17 million.
• Anticompetitive collusion complaint filed by the Ohio Attorney General.

Stakeholder Impact

• Shareholders face dilution risks if the company pursues further equity financing.
• Employees may be impacted by the temporary suspension of the Lansing, Michigan facility.

Next Steps

• Continue evaluating the impact of the April 2026 DOJ rescheduling order.
• Participate in upcoming DEA administrative hearings regarding broader rescheduling.
• Vigorously contest the Ohio Attorney General's complaint.
• Execute planned capital expenditures of approximately $20 million for 2026.

Key Dates

Recommendation

The company is navigating significant regulatory uncertainty and market-wide pricing pressure. While the resolution of the GTI arbitration is a positive step, the widening net loss and reliance on potential future capital raises suggest a cautious 'hold' stance until the impact of federal rescheduling becomes clearer.

Keywords

Ascend Wellness, AAWH, Cannabis, Multi-state operator, Q1 2026 earnings, Schedule III rescheduling, 280E tax